封面
市場調查報告書
商品編碼
1197207

腦積水分流器市場-增長、趨勢、COVID-19 影響和預測 (2023-2028)

Hydrocephalus Shunts Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內,腦積水分流器市場的複合年增長率預計為 8%。

世界面臨 COVID-19 的巨大威脅。 據世界衛生組織 (WHO) 稱,COVID-19 具有傳染性,許多感染該病毒的人會出現輕度至中度呼吸道疾病。 COVID-19的爆發對腦積水分流器市場產生了重大影響。 世界各地的封鎖措施減少了公民的流動。 臨床研發試驗和手術也受到影響,因為非緊急程序被推遲以減輕醫療基礎設施的壓力。 根據 Neurology Online Journal 發表的一項研究,到 2020 年,COVID-19 可能會在新的神經系統疾病的發展中發揮作用。 新殘疾的增加與更高的院內死亡風險和更低的提前出院可能性相關。 在這項研究中,606 名被診斷患有腦部或其他神經相關病症的成年 COVID-19 患者在感染的任何時間都受到密切隨訪。 結果造成了範圍廣泛的傷害,從因體內氧氣含量低導致的暫時意識模糊到嚴重情況下的中風和癲癇發作不等。 這些因素可能對研究市場產生積極影響。

市場的增長歸因於人口老齡化、大腦和神經系統疾病患病率上升以及先進可編程閥門的日益普及。 神經外科醫生傾向於使用最先進的分流器、防虹吸裝置和先進的可編程閥門。 防虹吸裝置有助於避免對腦脊液的虹吸效應。 腦部疾病的增加增加了對用於治療腦積水的先進分流器的需求。 例如,根據美國生物化學與分子生物學學會 2021 年 3 月發表的一篇論文,美國每年約有 280 萬人遭受創傷性腦損傷 (TBI),約有 28 萬人住院治療。 每天大約有 50,000 例死亡病例和 155 人死於與 TBI 相關的傷害,這促進了市場的增長。 多家公司將重點放在產品發布、產品批准和擴大其神經外科產品組合上,預計將推動腦積水分流器市場的發展。 然而,與使用腦積水分流器感染相關的問題可能會阻礙市場增長。

腦積水分流術的市場趨勢

預計在預測期內腦積水導管將主導市場

導管是腦積水管理的重要組成部分,某些患者群體發生分流感染的風險增加。 導管將腦脊液 (CSF) 從 CSF 過多的區域轉移到 CSF 被吸收的身體區域。

近端導管(腦室或腰椎導管)通過其起點處的一系列小孔從腦室或腰椎脊髓囊中排出多餘的腦脊液。 遠端導管通常留在腹腔內。 然而,它們可以放置在更適合將腦脊液排入血液的地方,例如心臟或胸腔(肺)。

這些設備在解決生物相容性、感染和污染問題方面的技術進步預計將促進這一細分市場的增長。 例如,一些分流導管浸有抗生素以降低術後感染的發生率,例如CODMAN BACTISEAL導管和Medtronic Ares導管。 Ares 抗生素浸漬導管可有效抵抗細菌定植。

此外,目前的研究主要集中在腦積水導管的潛在重新設計上,這可能會促進這一細分市場的增長。 例如,2020 年,麻省理工學院的研究人員在英國皇家學會界面雜誌上發表了一篇論文,提出並驗證了腦積水導管的新設計原則。 該設計試圖克服這些設備的核心挑戰,即腦積水導管的周期性堵塞。 這種新的設計原則可以防止腦分流術中的導管失效。

這些產品作為治療腦積水和其他腦部疾病的潛在產品而受到廣泛關注。 因此,這些因素可能會在預測期內顯著推動該行業的增長。

預計在預測期內北美將佔據很大的市場份額

由於腦積水患者數量的增加以及對神經系統疾病管理的日益關注,預計北美將佔據很大的市場份額。 據腦積水協會估計,2019 年美國將有 100 萬人患有腦積水,每 1000 名嬰兒中就有 1 人患有腦積水,這促使腦積水分流術的採用和該地區的增長將得到促進。

在美國市場增長的背景下,老年人口增加,腦部和神經系統疾病患病率增加,先進可編程閥門的採用率增加。 受此類疾病影響的人口比例很高,預計將推動對這些產品的需求。 多個參與者對產品發布、批准和擴展其神經外科產品組合的關注將推動美國的腦積水分流器市場。 例如,2020 年 Aesculap Inc. 與 Christoph Miethke GmbH & Co. 合作推出了 M.blue 分流器。 KG推出最新一代腦積水瓣膜技術“M.blue Valve”。 其獨特的重力技術集成到一個固定的壓差裝置和一個閥門中,從而實現了一種簡單的、與位置無關的解決方案。

此外,不斷上漲的醫療成本和完善的醫療基礎設施極大地推動了該地區市場的增長。

腦積水分流器市場競爭對手分析

腦積水分流術市場競爭適中,由幾家大型企業組成。 從市場份額的角度來看,幾家主要參與者目前主導著市場,其中包括 Christoph Miethke GmbH & Co.KG、Medtronic PLC、Sophysa、Tokibo、Spiegelberg GmbH & .Braun Melsungen AG、Integra LifeSciences Corporation、強生。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 腦部和神經系統疾病的患病率上升
    • 老年人口增加
    • 更多地採用先進的可編程閥門
  • 市場製約因素
    • 分流功能障礙、分流感染
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:百萬美元)

  • 按產品類型
    • 腦積水閥
      • 壓力控制閥
      • 固定壓力閥
    • 腦積水導管
  • 按年齡段
    • 兒科
    • 成人
  • 最終用戶
    • 醫院
    • 門診手術中心
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東
    • 南美洲

第六章競爭格局

  • 公司簡介
    • Christoph Miethke GmbH & Co. KG
    • Medtronic PLC
    • Sophysa
    • Tokibo Co. Ltd
    • Spiegelberg GmbH & Co. KG
    • B. Braun Melsungen AG
    • Integra LifeSciences Corporation
    • Johnson & Johnson

第7章 市場機會今後動向

簡介目錄
Product Code: 68434

The hydrocephalus shunts market is expected to register a CAGR of 8% during the forecast period.

The world has been facing the huge threat of COVID-19. As per the World Health Organization (WHO), COVID-19 is infectious, and most people infected by the virus experience mild to moderate respiratory illness. The COVID-19 outbreak had a significant impact on the hydrocephalus shunts market. The lockdown measures across the world resulted in decreased public mobility. They also impacted the clinical R&D studies and surgeries, as the procedures that were non-immediate were postponed to decrease the burden on healthcare infrastructure. As per the study published by the Neurology Online Journal, in 2020, COVID-19 could potentially be responsible for the patients developing new neurological disorders. The increase in new disorders resulted in a higher risk of in-hospital mortality and decreased likelihood of being discharged sooner. The study closely monitored 606 adult COVID-19 patients diagnosed with brain or other nerve-related medical conditions at any point of their infection. The injuries incurred ranged from temporary confusion due to low body-oxygen levels to stroke and seizures in serious cases. Such factors may positively influence the market studied.

The market's growth is attributed to the growing geriatric population, a rising prevalence of brain and neurological disorders, and the increasing adoption of advanced programmable valves. Neurosurgeons are inclining toward the latest technology shunts, antisiphon devices, and advanced programmable valves. Antisiphone devices help in avoiding siphon effects over cerebrospinal fluid. The increasing prevalence of brain disorders is leading to high demand for advanced shunts for treating hydrocephalus. For instance, according to an article published by the American Society for Biochemistry and Molecular Biology in March 2021, in the United States, about 2.8 million people sustain a traumatic brain injury (TBI) every year, with some 280,000 resulting in hospitalizations. Approximately 50,000 are fatal cases causing 155 deaths every day from TBI-related injuries, which are contributing to the market's growth. Product launches, product approvals, and an increased focus by several players on expanding product portfolios in neurosurgery are anticipated to boost the hydrocephalus shunts market. However, issues regarding the infections caused using hydrocephalus shunts may hamper the market's growth.

Hydrocephalus Shunts Market Trends

Hydrocephalus Catheters are Expected to Dominate the Market During the Forecast Period

Catheters are an important part of managing hydrocephalus, and certain patient populations are at greater risk of developing shunt infections. Catheters divert cerebrospinal fluid (CSF) from the site with an excess volume of CSF to a location within the body where the CSF will be absorbed.

The proximal catheter (ventricular or lumbar catheter) drains excess CSF from the ventricles or the lumbar spinal sac through rows of small holes at its origin. Distal catheters are typically placed in the abdominal cavity. However, they can also be placed in the heart, pleural cavity (lungs), and other suitable locations where CSF is drained into the bloodstream.

Technological advancements in these devices to combat the issues of biocompatibility, infection, and fouling are expected to contribute to the segment's growth. For instance, some shunt catheter is impregnated with antibiotics to reduce the incidence of infection during the post-operative period, such as the CODMAN BACTISEAL catheter and the Medtronic Ares catheter. The Ares antibiotic-impregnated catheters help reduce bacterial colonization.

In addition, current research focuses on the potential redesign of the hydrocephalus catheters, which may boost the segment's growth. For instance, in 2020, MIT researchers published a paper in the Journal of the Royal Society Interface, which proposes and validates a new design principle for hydrocephalus catheters. The design seeks to overcome a central challenge of these devices where they regularly become clogged. The new design principle could prevent catheter failure in brain shunts.

These products have attracted a significant amount of attention due to their potential prospects in the treatment of hydrocephalus and other brain disorders. Thus, such factors may boost the segment's growth significantly over the forecast period.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

North America is expected to hold a significant market share due to the rise in the number of patients with hydrocephalus and the growing emphasis on the management of neurological disorders. As per the Hydrocephalus Association, in 2019, an estimated 1 million people in the United States were affected by hydrocephalus, and 1 in every 1,000 babies had hydrocephalus, thus leading to the adoption of hydrocephalus shunts and promoting the growth in this region.

The growth of the US market is attributed to the rising geriatric population, rising prevalence of brain and neurological disorders, and increasing adoption of advanced programmable valves. Such a large population base suffering from the disease is expected to drive the demand for these products. Product launches, approval, and increased focus by several players on their expanding product portfolios in neurosurgery will propel the US hydrocephalus shunts market. For instance, in 2020, Aesculap Inc., in partnership with Christoph Miethke GmbH & Co. KG, launched the M.blue Valve, the latest generation of hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution.

Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are fueling the regional market's growth to a large extent.

Hydrocephalus Shunts Market Competitor Analysis

The hydrocephalus shunts market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market, including Christoph Miethke GmbH & Co. KG, Medtronic PLC, Sophysa, Tokibo Co. Ltd, Spiegelberg GmbH & Co. KG, B. Braun Melsungen AG, Integra LifeSciences Corporation, and Johnson & Johnson.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Brain and Neurological Disorder
    • 4.2.2 Increase in Geriatric Population
    • 4.2.3 Increasing Adoption of Advanced Programmable Valves
  • 4.3 Market Restraints
    • 4.3.1 Shunt Malfunction and Shunt Infection
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Hydrocephalus Valves
      • 5.1.1.1 Adjustable Pressure Valves
      • 5.1.1.2 Fix Pressure Valves
    • 5.1.2 Hydrocephalus Catheters
  • 5.2 By Age Group
    • 5.2.1 Pediatric
    • 5.2.2 Adult
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.2 Europe
    • 5.4.3 Asia-Pacific
    • 5.4.4 Middle-East
    • 5.4.5 South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Christoph Miethke GmbH & Co. KG
    • 6.1.2 Medtronic PLC
    • 6.1.3 Sophysa
    • 6.1.4 Tokibo Co. Ltd
    • 6.1.5 Spiegelberg GmbH & Co. KG
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 Integra LifeSciences Corporation
    • 6.1.8 Johnson & Johnson

7 MARKET OPPORTUNITIES AND FUTURE TRENDS